Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bright Minds Biosciences Inc. - common stock (NQ:DRUG)

35.35 -1.15 (-3.15%)
Streaming Delayed Price Updated: 9:40 AM EDT, Mar 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bright Minds Biosciences Inc. - common stock

< Previous 1 2 3 4 Next >
Biotechs on the Brink: 2 Stocks With Huge Potential
BriaCell Therapeutics and Recursion Pharmaceuticals are two biotech firms that may be poised for success in 2025; risk-tolerant investors might keep an eye out. 
Via MarketBeat
This Prudential Financial Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Meet the Biotech Stock That Has Generated Nvidia-Like Returns in Less Than a Month
The reason for the stock's rapid ascent is a mystery. 
Via The Motley Fool
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank?
A look at the most-searched tickers on Benzinga Pro for the month of October. Donald Trump and biotech stocks joined the top 10. 
Via Benzinga
Topics Government
Exposures Political
What's Going On With Bright Minds Biosciences Stock?
Bright Minds Biosciences Inc (NASDAQ:DRUG) shares are trading higher again after soaring last week. The company on Monday announced a new collaboration with brain health-focused AI company Firefly... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Crude Oil Down Over 1%; American Express Shares Fall After Q3 Results
Via Benzinga
Exposures Fossil Fuels
What's Going On With Bright Minds Biosciences Stock Friday?
Bright Minds Biosciences shares are moving higher on Friday. The company announced a $35 million non-brokered private placement. 
Via Benzinga
Dow Falls Over 100 Points; Netflix Posts Upbeat Results
Via Benzinga
Topics Stocks
Exposures US Equities
Firefly Neuroscience And Bright Minds Advance Phase 1 Study With AI-Driven Data Analysis
Firefly Neuroscience partners with Bright Minds Biosciences to analyze positive Phase 1 data of BMB-101 using advanced AI technology, setting the stage for Phase 2 trials. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Dow Jumps 250 Points; U.S. Bancorp Earnings Top Views
Via Benzinga
Topics Stocks
Exposures US Equities
US Stocks Mixed; Abbott Reports Better-Than-Expected Q3 Results
Via Benzinga
Why Ericsson Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Bright Minds Biosciences Reports Improved Financial Position For Q3 Amid Ongoing R&D Efforts
Bright Minds Biosciences reports a significant reduction in net losses for Q3 2024 while advancing its R&D programs focused on serotonergic therapies for CNS disorders. 
Via Benzinga
DRUG Stock Earnings: Bright Minds Biosciences Reported Results for Q3 2024
Bright Minds Biosciences just reported results for the third quarter of 2024. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to dive into the biggest pre-market stock movers for Monday morning with all of the latest news affecting shares today! 
Via InvestorPlace
DRUG Stock Earnings: Bright Minds Biosciences Reported Results for Q2 2024
Bright Minds Biosciences just reported results for the second quarter of 2024. 
Via InvestorPlace
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
Via Benzinga
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Via Benzinga
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
Via Benzinga
Topics Economy
Exposures Interest Rates
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
Via Benzinga
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
Via Benzinga
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
Via Benzinga
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian... 
Via Benzinga
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD 
Via Benzinga
Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More
Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury 
Via Benzinga
Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More
President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also... 
Via Benzinga
Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More
Biden To Decide On Psychedelic Therapy Bill 
Via Benzinga
Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More
John Lennon Remembered 43 Years After His Murder In New York, Psychedelic Adventures & Enduring Legacy 
Via Benzinga
Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
Defense Dept. Funds Ketamine Study For PTSD Treatment  
Via Benzinga
Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More
GOP Candidate Vivek Ramaswamy Wants Legal Psychedelics And Cannabis For PTSD In New Veterans Plan 
Via Benzinga
Topics Cannabis
Exposures Cannabis
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.